MedTrace Logo

Safety of Human Embryonic Stem Cell (hESC)-Derived Mesenchymal Stem Cells in Interstitial Cystitis

NCT04610359 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 3

Last updated 2020-10-30

No results posted yet for this study

Summary

This study primarily aimed to evaluate the safety of human embryonic stem cell (hESC)-derived mesenchyma stem cells in interstitial cystitis.

Conditions

  • Interstitial Cystitis
  • Stem Cell Transplant
  • Mesenchymal Stem Cell

Interventions

DRUG

MR-MC-01

Submucosal injection of 2.0 x 10,000,000/5ml (1mL \* 5 sites)

Sponsors & Collaborators

  • MIRAE CELL BIO

    collaborator UNKNOWN

  • Asan Medical Center

    lead OTHER

Principal Investigators

  • Myung-Soo Choo, M.D, Ph.D · Professor, Asan Medical Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
20 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-10-20
Primary Completion
2022-10-31
Completion
2022-12-31

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04610359 on ClinicalTrials.gov